Surmodics | SRDX - Selling And Administration Expenses


Surmodics reported $11.4M in Selling and Administration Expenses for its fiscal quarter ending in June of 2025.





Selling And Administration Expenses Change Date
Abbott USD 3.27B 138M Mar/2026
Align Technology USD 465.34M 23.67M Mar/2026
Anika Therapeutics USD 10.01M 14K Dec/2025
Arrowhead Research USD 41.74M 4.28M Mar/2026
Artivion USD 55.75M 4.54M Dec/2025
Baxter International USD 728M 33M Mar/2026
Boston Scientific USD 1.78B 53M Mar/2026
EDAP TMS EUR 8.81M 1.57M Sep/2025
Edwards Lifesciences USD 522.2M 80.7M Mar/2026
Haemonetics USD 109.15M 7.54M Dec/2025
Heron Therapeutics USD 23.74M 605K Dec/2025
J&J USD 6.03B 719M Mar/2026
Merit Medical Systems USD 110.47M 4.36M Mar/2026
Mesa Laboratories USD 27.31M 380K Sep/2024
Nektar Therapeutics USD 10.17M 10.17M Dec/2025
Option Care Health USD 174.56M 2.42M Mar/2026
Stryker USD 2.15B 17M Mar/2026
Surmodics USD 11.4M 3.18M Jun/2025
Trinity Biotech USD 6.19M 2.18M Sep/2025